SciSparc shares surge 50.34% premarket after announcing acquisition of MUSE GERD device patents via 19.99% equity deal.

SciSparc (SPRC) surged 50.34% in premarket trading following the announcement of a definitive agreement to acquire a portfolio of patents for the MUSE™ single-use endoscopic device, designed to treat GERD. The transaction, valued at 19.99% equity, grants access to a $2.5 billion market projected to grow to $3.03 billion by 2030. The company plans immediate commercialization post-closing on March 8, 2026, and aims to replicate Xylo’s successful licensing model in Greater China across high-growth regions. This strategic expansion into a lucrative medical device sector likely drove the sharp premarket rally, overshadowing earlier Nasdaq non-compliance concerns, as the acquisition signals potential revenue diversification and long-term value creation.